

AD_____

Award Number: W81XWH-07-1-0456

TITLE: Novel targeted immunotherapy for CML blast cells

PRINCIPAL INVESTIGATOR: Pappanaicken R. Kumaresan, Ph.D.

CONTRACTING ORGANIZATION: University of California, Davis
Davis, CA 95618

REPORT DATE: June 2008

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE 30-06-2008		2. REPORT TYPE Annual		3. DATES COVERED 1 JUN 2007 - 31 MAY 2008	
4. TITLE AND SUBTITLE Novel targeted immunotherapy for CML blast cells				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-07-1-0456	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Pappanaicken R. Kumaresan, Ph.D. Email: pkumaresan@ucdavis.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of California, Davis Davis, CA 95618				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT An emerging problem in chronic phase CML is molecular persistence. It is mainly due to the quiescent stem cell population that are completely insensitive to Imatinib therapy. We have developed a novel immunotherapy against CML. We have screened One-Bead-One-Compound (OBOC) combinatorial libraries and identified cyclic peptide ligands that are bind CML cancer cells. These ligands will then be ligated to the N-termini of the engineered Fc fragment of human immunoglobulin in a site-specific manner. We hypothesize that these cancer targeting ligand-Fc fragment conjugate (we call it "ligand-body") will bind to CML cells via the peptide or peptidomimetic ligand domain and the Fc immunoglobulin domain will be used to harness the anti-cancer innate immunity against CML cells in vivo. The innate immune system includes immune effector cells such as NK cells, NKT cells, macrophages and leukocytes and complement system. As mentioned in Aim1 and Aim 2, we have modified Fc domain for specific N-terminal ligation and produced modified protein for Ligand-body production. In the second year, functional characterization for the ligand-body will be performed.					
15. SUBJECT TERMS None listed.					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	8	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	8
Reportable Outcomes.....	8
Conclusion.....	8
References.....	
Appendices.....	

Novel targeted immunotherapy for CML blast cells

(Fist year Progress report (June-2007 to May 2008))

1. INTRODUCTION: An emerging problem in chronic phase CML is molecular persistence. It is mainly due to the quiescent stem cell population that are completely insensitive to Imatinib therapy. We have developed a novel immunotherapy against CML. We have screened One-Bead-One-Compound (OBOC) combinatorial libraries and identified cyclic peptide ligands that bind CML cancer cells. These ligands will then be ligated to the N-termini of the engineered Fc fragment of human immunoglobulin in a site-specific manner. We **hypothesize** that these cancer targeting ligand-Fc fragment conjugate (we call it “ligand-body/ chembody”) will bind to CML cells via the peptide or peptidomimetic ligand domain and the Fc immunoglobulin domain will be used to harness the anti-cancer innate immunity against CML cells in vivo. The innate immune system includes immune effector cells such as NK cells, NKT cells, macrophages and leukocytes and complement system.

The **specific Aims** of the project are:

Aim1: Construction of Fc with N-terminal cysteine for site-specific ligand ligation. Using site-directed mutagenesis, cysteine will be incorporated into the N-terminal end of Fc fragment. DNA construct containing CH2 and CH3 regions of the human IgG1 (corresponding to Fc fragment) from genomic DNA amplified by PCR and cloned with CD5 leader sequences called pCD5lneg1 vector has been provided to us as a kind gift from Dr. Brain Seed. He and his associates have used it to construct several chimeric-human IgG fusion protein (22) (reprints attached). For large-scale production of modified human IgG Fc fragment will be performed, by transfecting CsCl2 purified CD5lneg1 pDNA into COS-7 cells and collect the serum free supernatant on day 4, day 6 and day 8. Modified human IgG1-Fc fragment will be purified by protein-A-agarose affinity column. Glyoxylyl-linker-ligand (identified from aim 2) will be conjugated to the N-terminal cysteine via a site-specific thiazoline ring formation reaction to form ligand-body (aim 3).

Aim2: Identification and optimization of CML specific ligands.

Aim3: Preparation and biological characterization of ligand-body.

2. BODY: Chemical antibodies (also noted as chembody) were made by conjugating targeting ligands to immunoglobulin (IgG). Site specific and non-site specific conjugation methods were used to make chembodies. Progress report is broadly categorized in to two sub headings:

- (1) Construction and purification of N-terminal cysteine mutated Fc-fragment of human IgG1 (hIgG1-Cys-Fc).
- (2) Conjugation of targeting ligands to hIgG1-Cys-Fc, hIgG1-Fc and hIgG1
 - 2.1: N-terminal cysteine site specific conjugation
 - 2.2: non-site specific conjugation.

(1) Construction and purification of N-terminal cysteine mutated Fc-fragment of human IgG1 (cys-Fc-hIgG1).

Conjugation of the targeting ligand at N-terminal site of the IgG is preferred to protect IgG biological properties. Amine group conjugation at amino terminal is often interfered by the primary amine groups of lysine. To make it site specific a cysteine amino acid was introduced at the N-terminal by site directed mutagenesis (promega). N-terminal cysteine was used for site-specific conjugation.

Site directed mutagenesis: Human IgG1-Fc fragment expressing pFuse vector (Fig.1) (Invivogen) has been used to make N-terminal cysteine (Ig). The primers are designed and site directed mutagenesis was performed as described by protocol (Quick changeTM site-directed mutagenesis kit, cat# 200518, Promega). The primer sequences are shown in Table-1. Both primers bind at the same position of pFuse vector (611-653) and first amino acid after the signal sequence is mutated to cysteine. The native pDNA served as templates for PCR was digested by DpnI restricted endonuclease (RE). The RE digested PCR product was transformed to high efficiency competent cells (bluescript) and bacterial clones were selected on LB medium containing Zeocin 200 µg/mL. Plasmid DNA was isolated from positive clones and sequenced at UC Davis sequence facility to

conform the mutation. Five clones were selected and labeled as hIgG1-cys-21 to 25 respectively. One of the sequence alignment are shown in Table-1. Plasmid DNA of the mutated clone was used to transfect mammalian cell lines CHO (Chinese Hamster Ovary) by lipofectamine-2000 and stably hIgG-Fc expressing clones were selected by growing in DMEM medium supplemented with 10% FBS and zeomycin antibiotic at 500 µg/mL.

1.1 Mutated human IgG1-Fc (hIgG1-Cys-Fc) protein production: Expression level of hIgG1-Cys-Fc fragment was determined by performing sandwich ELISA method. Serum free supernatant of positive clones




were collected and incubated for 1 h in protein-G coated plates (Pierce biotechnology). Supernatants were aspirated and alkaline phosphatase (AP) conjugated anti-human Fc specific antibody (Bethyl labs, TX) was added and incubated for 30 min at room temperature. Three washes were given with PBS, and DAB substrate was added to develop color. Based on the color intensity, highly expressing positive clones were selected for hIgG-Cys-Fc protein production. Serum free supernatants from highly expressing clones were collected and hIgG1-Cys-Fc protein was purified by Protein-G affinity columns (Biorad). The purity of the protein was checked by separating in 10% SDS-PAGE reduced electrophoresis and transferred to a nitrocellulose membrane. Another gel was stained with Coomassie blue and gel pattern was documented.

Table 1. Mutagenesis primer sequences

Primer	Sequences 611-653 of pFUSE-hIgG1-FC2 (Invivogen)
Fc-cys-FP (Forward primer)	5'-CTT GTC ACG AAT TCG TGC TCG GCC ATG GTT AGA TCT GTG GAG-3'
Fc-cys-Rp (Reverse primer)	5'-CTC CAC AGA TCT AAC CAT GGC CGA GCA CGA ATT CGT GAC AAG-3'
Sequence Alignment	605615625 pFUSE-hIgGTTGCACTAAGTCTTGCACTTGTCACGAATT hIgG1-cys-25TTGCACTAAGTCTTGCACTTGTCACGAATT 635645655 CGATATCGGCATGGTTAGATCTGACAAAA CGTGTCTCGGCCATGGTTAGATCTG-----
Sequences of pFUSE-hIgG1-Fc2 and hIgG1-Cys-Fc-25 and its alignments are in the table-1. The sequence alignments are done by using Bioedit software. Mutated “Cys” is shown in red color.	

Western blot was developed by AP-conjugated goat anti-human Fc-specific antibody (Fig 2) using chemiluminescence kit (perkin-elmer, CDP star kit). In the reducing gel, ~25 kD band showed positive to anti-human IgG-Fc specific antibodies suggests that the expressed protein is hIgG-Cys-Fc fragment. Because of the reducing gel it ran in monomeric form at ~25 kD. The estimated MW of the protein is hIgG-Cys-Fc is ~ 50 kD. After conforming with western blot analysis, hIgG1-cys-Fc protein has taken for conjugation studies.



(2) Conjugation of targeting ligands to hIgG1-Cys-Fc, hIgG1-Fc and hIgG1

2.1 Synthesis of targeting ligands

2.2 N-terminal cysteine site specific conjugation

2.3 non-site specific conjugation

The LLP2A-a lymphoma targeting ligand was selected to make a prototype of chembody. LLP2A is a targeting ligand for $\alpha 4 \beta 1$ integrin receptor which is over expressed in lymphomas. The exact role of $\alpha 4 \beta 1$ integrin in cancer remains to be completely elucidated. It is hypothesized that it plays a major role in facilitating metastatic disease. For instance, it has been shown to be expressed only on proliferating cells during tumor development, not on quiescent cells. In B-CLL, $\alpha 4 \beta 1$ integrin is linked to drug resistance and apoptosis resistance. In a murine model of myeloma, a monoclonal antibody to $\alpha 4 \beta 1$ integrin was shown to inhibit tumor growth and metastasis, without any effect on normal hematopoietic cells. Based on these findings, $\alpha 4 \beta 1$ is a promising target for the treatment of both cancer and certain inflammatory diseases.


2.1 Synthesis of LLP2A targeting ligand: LLP2A-maleimide and LLP2A-glyoxylyl was synthesized using synthetic Fmoc protected chemistry. After synthesis the LLP2A-derivatives were purified through C18, HPLC column. MALDI-TOF mass spectrometry revealed its mass is 1550 Da which is close to the calculated mass. The structure and schematic representation of LLP2A-maleimide synthesis is shown in fig 3.

2.2. N-terminal cysteine site specific conjugation with LLP2A-maleimide :

Maleimide can react with sulfhydryl functional groups and form a stable thio ether bonds. Maleimide reactions are specific for sulfhydryl groups in the pH range 6.5-7.5, at pH 7.0, the reaction of the Maleimide with sulfhydryls proceeds at a rate 1000 times greater than its reaction with amines. This type of conjugation is beneficial to proteins which has few cysteines especially immunoglobulins (Igs). The cysteines present in Ig proteins are either present in the inner groove or formed S-S double bonds with other cysteines. By using reducing agents such as dithiothreitol (DTT), β -mercaptoethanol, TCEP up to eight functional -SH groups can be produced for conjugation. The disulfide bond that holds two heavy chains together has been in use to couple AP or HRPO enzymes to conjugate in antibody for immunohistochemistry. Conjugation done using hinge-area -SH groups will orient the attached protein or other molecules away from the antigen binding regions, thus preventing blockage of these sites and preserving activity. At the same time conjugation at hinge region and CH2 domain of the Abs will diminish other functions of Ab such as recruitment of host immune cells to fight against abnormal cells. This can be overcome by introducing cysteine amino acid at the N-terminal end with free -SH functional group which is an ideal for site specific conjugation. We have used cysteine introduced hIgG-Fc (hIgG1-cys-Fc) for conjugating targeting ligands either by maleimide conjugation or by glyoxylyl conjugation.



Fig 4. Schematic representation of LLP2A-chembody



3. KEY RESEARCH ACCOMPLISHMENTS:

1. Modified Fc domain of the human IgG (hIgG-cys-Fc) was made by site-directed mutagenesis.
2. hIgG-cys-Fc was stably transfected and purified from the cell culture supernatant.
3. A prototype of ligand-body (chembody) was made by conjugating with lymphoma targeting ligand (LLP2A).
4. The conjugation was verified by SDS-PAGE and western blot analysis.

4. REPORTABLE OUTCOMES:

Pappanaicken R. Kumaresan, Aimin Song, Jan Marik, Juntao Luo, Kit S. Lam (2008) Evaluation of ketone-oxime conjugation method for developing On-demand cleavable immunoconjugates for radio immunotherapy. Bioconjugate chemistry, (Inpress).

5. CONCLUSION: We have successfully constructed chemical antibodies against lymphoma. Functional studies of the chemical antibodies such as tumor targeting and effector cell recruitment will be evaluated. The same studies will be repeated by conjugating with CML-blast targeting ligand against minimal residual disease CML cells.

6. REFERENCE: